Skip to main content

Table 7 Comparison between patients who developed pazopanib-related cardiovascular toxicity after excluding hypertension

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Patient Characteristics

Pazopanib-induced non-HTN CV toxicity (N = 12)

No Pazopanib-induced non-HTN CV toxicity (N = 23)

P Value

Male Gender

5 (42)

15 (65)

0.282

Age, years

66 [61-71]

57 [52-65]

0.006

LVEF, %

*60 [59-67]

**62.5 [59-66]

0.712

Systolic BP, mm Hg

124.1 [120.8-130.8]

127.7 [122-132.6]

0.728

Diastolic BP, mm Hg

70.0 [65.9-73.5]

72 [67.9-79.3]

0.297

Heart Failure

0 (0)

2 (9)

0.536

LV Dysfunction

4 (33)

3 (13)

0.200

Diabetes Mellitus

5 (42)

10 (43)

1

Hypertension

7 (58)

14 (61)

1

Dyslipidemia

8 (67)

9 (39)

0.164

GFR < 60 mL/min/1.73 m2

9 (75)

11 (48)

0.163

CAD/PAD

3 (25)

2 (9)

0.313

CVA/TIA

3 (25)

0 (0)

0.034

Dysrhythmia

3 (25)

4 (17)

0.670

Thromboembolism

1 (8)

6 (26)

0.380

Smoker*, n (%)

7 (58)

13 (57)

1

BMI (kg/m2)

27.6 [23.6-31.8]

28.5 [21.9-32.9]

0.627

ACEIs or ARBs

6 (50)

8 (35)

0.383

Beta Blockers

4 (33)

8 (35)

1

Statin

6 (50)

7 (30)

0.256

Pazopanib dose reduction

3 (25)

3 (13)

0.391

Follow-up time, months

11.7 [4.2-20.9]

6.9 [2.1-17.7]

0.509

  1. ACEI angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, BMI body mass index, CAD/PAD coronary artery disease/peripheral arterial disease, CCBs calcium channel blockers, ECOG Eastern Cooperative Oncology Group performance status, LVEF left ventricular ejection fraction, GRF glomerular filtration rate; Data presented as a percent (%) or median [1st quartile-3rd quartile]
  2. * N = 9; ** N = 16
  3. aCurrent or prior smoking history